Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FEN1 | P39748 | 16/20 | 0.37 |
| ▸ | ALOX5AP | P20292 | 14/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 2/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | THRA | P10827 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29414843 | 1.00 | FEN1 (0.37) | FEN1ALOX5APMAPTTHRBHSD11B1 | |
| SCHEMBL23421620 | 0.97 | FEN1 (0.35) | FEN1ALOX5APMAPTTHRBHSD11B1 | |
| SCHEMBL29986640 | 0.97 | FEN1 (0.35) | FEN1ALOX5APMAPTTHRBHSD11B1 | |
| SCHEMBL29987261 | 0.96 | THRB (0.35) | FEN1ALOX5APMAPTTHRBHSD11B1 | |
| SCHEMBL31524123 | 0.94 | THRA (0.33) | FEN1MAPTTHRBTHRA | |
| SCHEMBL21749432 | 0.94 | THRA (0.33) | FEN1MAPTTHRBTHRA | |
| SCHEMBL30297354 | 0.85 | THRA (0.35) | FEN1ALOX5APTHRBTHRA | |
| SCHEMBL24032513 | 0.84 | MAPT (0.33) | MAPT | |
| SCHEMBL28632953 | 0.83 | THRB (0.33) | MAPTTHRBHSD11B1THRA | |
| SCHEMBL23260087 | 0.83 | MAPT (0.32) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2025-10-02 | — | — | US | disclosed |
| EP-4523692-A2 | MODULATORS OF THR-SS AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| EP-3965884-B1 | MODULATORS OF THR-BETA WITH A DIOXO-1,2,4-TRIAZYL HEAD GROUP | ALIGOS THERAPEUTICS INC (US) | 2025-01-15 | — | — | EP | disclosed |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2024-12-31 | — | — | US | disclosed |
| US-20230167091-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND AND USE THEREOF | Shandong First Medical University & Shandong Academy Of Medical Sciences (CN) | 2023-06-01 | — | — | US | disclosed |
| US-20230167091-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND AND USE THEREOF | Shandong First Medical University & Shandong Academy Of Medical Sciences (CN) | 2023-06-01 | — | — | US | disclosed |
| WO-2022127779-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND AND USE THEREOF | 山东第一医科大学(山东省医学科学院) | 2022-06-23 | — | — | WO | disclosed |
| EP-3965884-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | Aligos Therapeutics, Inc. (US) | 2022-03-16 | — | — | EP | disclosed |
| US-20210355112-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2021-11-18 | — | — | US | disclosed |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | ALIGOS THERAPEUTICS, INC. (US) | 2021-08-17 | — | — | US | disclosed |
| WO-2021104288-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 昆药集团股份有限公司 | 2021-06-03 | — | — | WO | disclosed |
| WO-2021104288-A1 | 1,2,4-TRIAZINE-3,5-DIONE COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 昆药集团股份有限公司 | 2021-06-03 | — | — | WO | disclosed |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2020-11-12 | — | — | US | disclosed |
| WO-2020227549-A1 | MODULATORS OF THR-β AND METHODS OF USE THEREOF | ALIGOS THERAPEUTICS, INC. (US) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210355112-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | FEN1 3867/4885ALOX5AP 4526/4885MAPT 1399/4885 |
| US-20250304561-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | FEN1 3760/4885ALOX5AP 4544/4885MAPT 1383/4885 |
| US-20200354345-A1 | MODULATORS OF THR-BETA AND METHODS OF USE THEREOF | THRB, THRA, TRHR | FEN1 3867/4885ALOX5AP 4526/4885MAPT 1399/4885 |
| US-12180192-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | FEN1 4099/4885ALOX5AP 4545/4885MAPT 1243/4885 |
| US-20230167091-A1 | SUBSTITUTED PYRIDAZINONE COMPOUND AND USE THEREOF | THRB, TPO, TSHR | FEN1 3625/4885ALOX5AP 1695/4885MAPT 1274/4885 |
| US-11091467-B2 | Modulators of THR-β and methods of use thereof | THRB, THRA, TRHR | FEN1 4099/4885ALOX5AP 4545/4885MAPT 1243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.